Last reviewed · How we verify

NCT04445610

Measles Vaccine: Is There a Protective Role in COVID 19 Pandemic?

Status unknown Last updated 26 June 2020
What this trial tests

trial in Coronavirus (COVID-19) in 60 participants. Status unknown.

Timeline
1 July 2020
Primary endpoint
1 September 2020
1 November 2020

Quick facts

Lead sponsorAin Shams University
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment60
Start date1 July 2020
Primary completion1 September 2020
Estimated completion1 November 2020
Sites1 location across Egypt

Conditions studied

Sponsor

Ain Shams University

Who can join

Eligibility, any sex, with Coronavirus (COVID-19). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The following two mechanisms that explain the ability of measles vaccine to cause partial protection against COVID-19. The first is that measles vaccine may increase the ability of the immune system to fight off pathogens other than measles due to the generated bystander immunity that would enhance the overall immunity against the new coronavirus. The second is that SARS-CoV-2 is proven to have structure similarities with measles, which may cause cross-reactivity and immunity between measles vaccines and COVID-19, leading to partial protection against COVID-19 in vaccinated subjects

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Ain Shams University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04445610.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing